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Erratum
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated 
Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer: Erratum
A programming error resulted in the publishing of a number of errors in the article beginning on page 1625 of the November 2014 issue. The correct text of 
the “Time to Deterioration in Symptoms” section on page 1629 is:
The TTD event rate was observed to be 57% in the crizotinib arm, 67% in the pemetrexed subgroup, and 84% in the docetaxel subgroup. The median TTD 
for pain I n chest, dyspnea (QLQ-LC13), or cough as a composite end point was 4.5 months (95% CI, 3.0–6.9 months) for the crizotinib arm compared with 
1.8 months (95% CI, 1.1–3.0 months) for the pemetrexed subgroup, and 0.9 months (95% CI, 0.9–1.4 months) for the docetaxel subgroup. Treatment with 
crizotinib was associated with a longer TTD in symptoms of pain in chest, dyspnea, or cough compared with pemetrexed (HR, 0.624; 95% CI, 0.448–0.871; 
p = 0.088) (Figure 4A) or with docetaxel (HR, 0.347; 95% CI, 0.241–0.498; p < 0.001) (Figure 4B). When each symptom was analyzed separately, crizotinib 
was associated with a greater delay in TTD for pain in chest (median 20.8 months; 95% CI, 18.1 months—not reached [NR]) compared with pemetrexed 
(median 9.9 months; 95% CI, 5.8 months—NR; HR, 0.408; p = 0.0008) and docetaxel (median 2.3 months; 95% CI, 1.5 months; HR, 0.182; p < 0.001). 
Similarly, for dyspnea the median TTD for patients on crizotinib was 10.0 months (95% CI, 5.7–18.8 months) compared with a median of 2.8 months (95% 
CI, 1.8–5.3 months; HR, 0.584; p = 0.0088), for the pemetrexed subgroup and 1.5 months (95% CI, 1.0–3.5 months; HR, 0.400; p < 0.001) for the docetaxel 
subgroup. For cough, there was a longer TTD with crizotinib (median 18.8 months; 95% CI, 11.9–22.9; p < 0.05) than with docetaxel (median 5.5 months; 
95% CI, 2.5–NR; HR, 0.424; p = 0.0011), whereas there was no difference for crizotinib compared with pemetrexed (HR, 0.813; p = 0.398).
In addition, Figure 4 should have appeared as follows:
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